An updated patent review of STAT6 inhibitors and modulators (2020 – present)

INTRODUCTION: Signal Transducer and Activator of Transcription 6 (STAT6) is a critical transcription factor in the interleukin-4 (IL-4) and IL-13 signaling pathways and serves as a key pathogenic driver of type 2 (TH2) immune responses. Dysregulated STAT6 activity is implicated in asthma, atopic dermatitis, autoimmune diseases, eosinophilic disorders, and certain cancers. As such, targeting STAT6 presents a promising therapeutic strategy for these diseases. AREAS COVERED: This review provides a comprehensive analysis of patent strategies for targeting STAT6 from 2020 to the present. We categorize and evaluate chemical entities based on their core structural features, highlighting key motifs, major patent assignees, and the progression of lead candidates through preclinical and clinical development. EXPERT OPINION: Recent advances reflect a clear evolution from broad JAK/STAT pathway inhibitors toward highly selective STAT6-targeted agents. Although research and development in this area are progressing rapidly with significant achievements, key challenges remain - including optimizing pharmacokinetic properties, achieving tissue specificity, and mitigating off-target effects. The emergence of bifunctional degraders, such as PROTACs, represents a promising frontier for achieving complete and sustained pathway suppression. Future success will likely depend on combining innovative chemistry with sophisticated patient stratification biomarkers to translate potent STAT6 inhibition into safe, effective therapies.